Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy

‘Wave 1’ Drug Part Of Orexin Agonist Portfolio

 
• By Mandy Jackson
  
Waves crashing against the shoreline at sunset along the Western coast of Oahu
Takeda's TAK-994 could be its first Wave 1 R&D program to crash • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D